A Retrospective Analysis of Nonresponse to Daily Teriparatide Treatment

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 2016 Apr 9

PMID 27055464

Citations 8

Authors

R Niimi

A Nishihara

M Hasegawa

T Kono

A Sudo

Affiliations

Soon will be listed here.

Abstract

Unlabelled: Some patients with osteoporosis do not respond to teriparatide treatment. Prior bisphosphonate use, lower bone turnover marker (BTMs) concentrations, and lower early increases in BTMs were significantly associated with a blunted lumbar spine (LS) bone mineral density (BMD) response to daily treatment with teriparatide, although the impact was limited.

Introduction: Some osteoporosis patients do not respond to teriparatide treatment. To better understand the factors underlying treatment nonresponses, we compared nonresponders' and responders' characteristics.

Methods: We retrospectively analyzed 354 male and female patients with osteoporosis who were administered teriparatide (20 μg/day) for 24 months. The patients were categorized as responders (≥3 % lumber spine (LS) bone mineral density (BMD) increase) or nonresponders (<3 % LS BMD increase), and the groups were compared.

Results: The univariate analyses determined that prior bisphosphonate use, a lower baseline procollagen type I N-terminal propeptide (PINP) concentration and a lower urinary N-telopeptide of type I collagen (uNTX) concentration at baseline were significantly associated with teriparatide nonresponses, but these factors were not significant following multivariate analysis. Diminished early increases in the bone turnover markers (BTMs) were also related to nonresponses after teriparatide treatment began. In the nonresponders, the mean (standard deviation (SD)) absolute LS and femoral neck (FN) BMD changes were -0.002 g/cm(2) (0.032) and -0.010 g/cm(2) (0.045), respectively. In the responders, the mean (SD) absolute LS and FN BMD changes were 0.118 g/cm(2) (0.056) and 0.021 g/cm(2) (0.046), respectively. The serum PINP and uNTX levels increased rapidly in both groups, but the responders showed higher early absolute serum PINP and uNTX increases.

Conclusions: The factors associated with nonresponses were prior bisphosphonate use, lower baseline BTM levels, and lower early increases in the BTMs after starting teriparatide treatment, but the impact of these factors on achieving a ≥3 % LS BMD increase at 24 months was limited.

Citing Articles

Responders and non-responders to romosozumab treatment.

Tominaga A, Wada K, Kato Y, Okazaki K J Bone Miner Metab. 2024; .

PMID: 39645533 DOI: 10.1007/s00774-024-01570-y.

Risk factors for nonresponse to 2 years of denosumab administration in patients with osteoporosis: A retrospective single-center cohorts study.

Yamamoto A, Nagao M, Nishizaki Y, Maeda E, Ishijima M Health Sci Rep. 2024; 7(4):e1993.

PMID: 38585014 PMC: 10995440. DOI: 10.1002/hsr2.1993.

Nonresponder Considerations for Romosozumab Treatment.

Tominaga A, Wada K, Okazaki K, Nishi H, Terayama Y, Shimamoto S Calcif Tissue Int. 2023; 113(2):157-165.

PMID: 37138124 DOI: 10.1007/s00223-023-01087-y.

Factors associated with bone response to teriparatide in young postmenopausal women with osteoporosis.

Anna G, Anne-Lise F, Clemence D, Jean-Michel P, Florence T J Bone Miner Metab. 2023; 41(2):278-285.

PMID: 36894786 DOI: 10.1007/s00774-023-01412-3.

Efficacy of Switching From Teriparatide to Bisphosphonate or Denosumab: A Prospective, Randomized, Open-Label Trial.

Niimi R, Kono T, Nishihara A, Hasegawa M, Kono T, Sudo A JBMR Plus. 2018; 2(5):289-294.

PMID: 30283910 PMC: 6139701. DOI: 10.1002/jbm4.10054.

References

Krege J, Lane N, Harris J, Miller P . PINP as a biological response marker during teriparatide treatment for osteoporosis. Osteoporos Int. 2014; 25(9):2159-71. PMC: 4134485. DOI: 10.1007/s00198-014-2646-0. View

Niimi R, Nishihara A, Hasegawa M, Matsumine A, Kono T, Sudo A . Efficacy of the dynamic radiographs for diagnosing acute osteoporotic vertebral fractures. Osteoporos Int. 2013; 25(2):605-12. DOI: 10.1007/s00198-013-2456-9. View

Ettinger B, San Martin J, Crans G, Pavo I . Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res. 2004; 19(5):745-51. DOI: 10.1359/JBMR.040117. View

Niimi R, Nishihara A, Hasegawa M, Matsumine A, Nakamura T, Kono T . An algorithm using the early changes in PINP to predict the future BMD response for patients treated with daily teriparatide. Osteoporos Int. 2013; 25(1):377-84. DOI: 10.1007/s00198-013-2426-2. View

Heaney R, Watson P . Variability in the measured response of bone to teriparatide. Osteoporos Int. 2010; 22(6):1703-8. DOI: 10.1007/s00198-010-1376-1. View

Lindsay R, Scheele W, Neer R, Pohl G, Adami S, Mautalen C . Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med. 2004; 164(18):2024-30. DOI: 10.1001/archinte.164.18.2024. View

Cosman F, Wermers R, Recknor C, Mauck K, Xie L, Glass E . Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab. 2009; 94(10):3772-80. DOI: 10.1210/jc.2008-2719. View

Minne H, Audran M, Simoes M, Obermayer-Pietsch B, Sigurdsson G, Marin F . Bone density after teriparatide in patients with or without prior antiresorptive treatment: one-year results from the EUROFORS study. Curr Med Res Opin. 2008; 24(11):3117-28. DOI: 10.1185/03007990802466595. View

Obermayer-Pietsch B, Marin F, McCloskey E, Hadji P, Farrerons J, Boonen S . Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res. 2008; 23(10):1591-600. DOI: 10.1359/jbmr.080506. View

10.

Niimi R, Nishihara A, Hasegawa M, Matsumine A, Kono T, Sudo A . Usefulness of daily teriparatide treatment in elderly patients over 80 years of age. Osteoporos Int. 2016; 27(5):1869-74. DOI: 10.1007/s00198-015-3479-1. View

11.

Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M . Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab. 2001; 19(6):331-7. DOI: 10.1007/s007740170001. View

12.

Vestergaard P, Jorgensen N, Mosekilde L, Schwarz P . Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk--a meta-analysis. Osteoporos Int. 2006; 18(1):45-57. DOI: 10.1007/s00198-006-0204-0. View

13.

Niimi R, Nishihara A, Hasegawa M, Matsumine A, Kono T, Sudo A . Analysis of daily teriparatide treatment for osteoporosis in men. Osteoporos Int. 2015; 26(4):1303-9. DOI: 10.1007/s00198-014-3001-1. View

14.

Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R . Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med. 2005; 353(6):566-75. DOI: 10.1056/NEJMoa050157. View

15.

Gallagher J, Rosen C, Chen P, Misurski D, Marcus R . Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis. Bone. 2006; 39(6):1268-75. DOI: 10.1016/j.bone.2006.06.007. View

16.

Blumsohn A, Marin F, Nickelsen T, Brixen K, Sigurdsson G, Gonzalez de la Vera J . Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide. Osteoporos Int. 2010; 22(6):1935-46. PMC: 3092934. DOI: 10.1007/s00198-010-1379-y. View

17.

Orwoll E, Scheele W, Paul S, Adami S, Syversen U, Diez-Perez A . The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003; 18(1):9-17. DOI: 10.1359/jbmr.2003.18.1.9. View

18.

Chen P, Miller P, Delmas P, Misurski D, Krege J . Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res. 2006; 21(11):1785-90. DOI: 10.1359/jbmr.060802. View

19.

Lindsay R, Zhou H, Cosman F, Nieves J, Dempster D, Hodsman A . Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res. 2007; 22(4):495-502. DOI: 10.1359/jbmr.070104. View

20.

Borggrefe J, Graeff C, Nickelsen T, Marin F, Gluer C . Quantitative computed tomographic assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: results from the EUROFORS study. J Bone Miner Res. 2009; 25(3):472-81. DOI: 10.1359/jbmr.090820. View